MD4608C1 - Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate - Google Patents

Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate Download PDF

Info

Publication number
MD4608C1
MD4608C1 MDA20150031A MD20150031A MD4608C1 MD 4608 C1 MD4608 C1 MD 4608C1 MD A20150031 A MDA20150031 A MD A20150031A MD 20150031 A MD20150031 A MD 20150031A MD 4608 C1 MD4608 C1 MD 4608C1
Authority
MD
Moldova
Prior art keywords
pressure
bar
hyperbaric
inactivated
high pressure
Prior art date
Application number
MDA20150031A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD4608B1 (ro
MD20150031A2 (ro
Inventor
Николас Пьер Ив КАРБУЛЕК
Жильда Мериан
Рене Лабатю
Лионель Жерант
Original Assignee
Merial Inc.
Top Industrie S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc., Top Industrie S.A.S. filed Critical Merial Inc.
Publication of MD20150031A2 publication Critical patent/MD20150031A2/ro
Publication of MD4608B1 publication Critical patent/MD4608B1/ro
Publication of MD4608C1 publication Critical patent/MD4608C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/10—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress
    • A23B2/103—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress using sub- or super-atmospheric pressures, or pressure variations transmitted by a liquid or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01041—Sterol 24-C-methyltransferasee (2.1.1.41)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sustainable Development (AREA)
MDA20150031A 2012-08-30 2013-08-30 Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate MD4608C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261694968P 2012-08-30 2012-08-30
US201361830425P 2013-06-03 2013-06-03
PCT/US2013/057426 WO2014036345A2 (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Publications (3)

Publication Number Publication Date
MD20150031A2 MD20150031A2 (ro) 2015-10-31
MD4608B1 MD4608B1 (ro) 2018-12-31
MD4608C1 true MD4608C1 (ro) 2019-07-31

Family

ID=49162270

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150031A MD4608C1 (ro) 2012-08-30 2013-08-30 Dispozitiv hiperbaric şi metode de producere a vaccinurilor inactivate şi proteinelor recombinante repliate/solubilizate

Country Status (18)

Country Link
US (3) US9169302B2 (enExample)
EP (2) EP2890392B1 (enExample)
JP (2) JP6405308B2 (enExample)
KR (1) KR102208844B1 (enExample)
CN (3) CN104717976A (enExample)
AP (1) AP2015008331A0 (enExample)
AU (4) AU2013308623B2 (enExample)
BR (1) BR112015004463B8 (enExample)
CA (2) CA2883303A1 (enExample)
EA (1) EA031988B1 (enExample)
ES (1) ES2744709T3 (enExample)
HK (1) HK1211874A1 (enExample)
MD (1) MD4608C1 (enExample)
MX (3) MX358782B (enExample)
NZ (3) NZ715459A (enExample)
PH (1) PH12015500700B1 (enExample)
RU (1) RU2647568C2 (enExample)
WO (2) WO2014036349A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
ZA201501696B (en) 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
MX358782B (es) 2012-08-30 2018-09-04 Merial Inc Expresión de proteina ksac quimérica y método para producir proteínas solubles mediante alta presión.
EP2978447B1 (en) * 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CN104758944B (zh) 2015-04-02 2017-11-28 中国科学院过程工程研究所 一种疫苗制剂及其制备方法和用途
JP2018082987A (ja) * 2016-11-25 2018-05-31 株式会社日立製作所 ウイルス不活化方法及びウイルス不活化装置
JP2020152644A (ja) * 2019-03-18 2020-09-24 国立大学法人愛媛大学 Ｖｎａｒのリフォールディング方法およびｖｎａｒの製造方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112120012B (zh) * 2020-09-30 2022-03-22 广东康盾创新产业集团股份公司 一种car-t细胞冻存方法
BR102021000794A2 (pt) * 2021-01-15 2022-07-26 Fundação Oswaldo Cruz Proteína quimérica, kit, método para diagnóstico de leishmaniose, uso de uma proteína quimérica, composição vacinal contra leishmaniose visceral, e, uso de uma composição vacinal

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
AU4975699A (en) 1998-07-09 2000-02-01 University Technology Corporation High pressure refolding of protein aggregates and inclusion bodies
EP1180945A1 (en) 1999-05-28 2002-02-27 Universite Laval Inactivation of food spoilage and pathogenic microorganisms by dynamic high pressure
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
AU780979B2 (en) 1999-09-25 2005-04-28 Coley Pharmaceutical Gmbh Immunostimulatory nucleic acids
US7615617B2 (en) 1999-10-25 2009-11-10 University Of Delaware Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
AU2002246493A1 (en) 2000-08-10 2002-07-30 Boston Biomedica, Inc. Pressure cycling inactivation of pathogens in biological materials used for therapeutics or vaccines
US6635223B2 (en) 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
DE60133426T2 (de) * 2000-10-31 2008-11-13 BaroFold, Inc., Boulder Verbesserter zerfall und rückfaltung von proteinen mittels hohen drucks
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
SE525457C2 (sv) * 2002-06-24 2005-02-22 Flow Holdings Sagl Förfarande för åstadkommande av en tryckändring mellan två trycktillstånd, högtryckspressanordning samt användning av förfarande eller högtryckspressanordning
WO2005044301A2 (en) * 2003-11-05 2005-05-19 C.B.F. Leti, S.L. Unipersonal Use of specific histones for the treatment of parasitic diseases
US7993580B2 (en) 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
AU2006318435A1 (en) 2005-11-21 2007-05-31 Barofold, Inc. Devices and methods for high-pressure refolding of proteins
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
US20080161242A1 (en) 2006-09-15 2008-07-03 Randolph Theodore W High pressure treatment of proteins for reduced immunogenicity
US7829681B2 (en) 2007-04-05 2010-11-09 Barofold Inc. High-pressure inclusion body solubilization and protease clipping of recombinant fusion proteins
WO2008124134A2 (en) 2007-04-05 2008-10-16 Barofold, Inc. High-pressure refolding of proteins in the presence of binding partners
WO2009045553A1 (en) 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
AU2008348022B2 (en) * 2007-12-21 2015-03-05 Zoetis Services Llc Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
BRPI0800357A2 (pt) 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz método para produção de uma vacina estabilizada
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
EP2300051B1 (en) 2008-05-21 2014-11-12 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
WO2009155102A2 (en) 2008-05-30 2009-12-23 Barofold, Inc. Method for derivatization of proteins using hydrostatic pressure
US20110070219A1 (en) 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
CA2787320A1 (en) 2010-02-01 2011-08-04 Avure Technologies Ab High-pressure arrangement with locking element preventing rotation of load basket
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备
EP2600843B9 (en) 2010-07-19 2020-03-11 Pressure BioSciences, Inc. Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
MX358782B (es) * 2012-08-30 2018-09-04 Merial Inc Expresión de proteina ksac quimérica y método para producir proteínas solubles mediante alta presión.
ZA201501696B (en) * 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Also Published As

Publication number Publication date
MX2015002701A (es) 2015-12-01
CA2883303A1 (en) 2014-03-06
US20170081372A1 (en) 2017-03-23
MD4608B1 (ro) 2018-12-31
KR102208844B1 (ko) 2021-01-27
AU2013308627B2 (en) 2016-10-27
MX2015002699A (es) 2015-12-01
AU2017200301A1 (en) 2017-02-16
PH12015500700A1 (en) 2015-05-25
AU2017201724A1 (en) 2017-03-30
BR112015004463A2 (pt) 2017-08-08
CN104768577A (zh) 2015-07-08
MX381717B (es) 2025-03-13
AU2013308623B2 (en) 2017-03-02
JP6438396B2 (ja) 2018-12-12
NZ706288A (en) 2016-06-24
ES2744709T3 (es) 2020-02-26
EA201500275A1 (ru) 2015-07-30
CN104768577B (zh) 2020-06-09
HK1211873A1 (en) 2016-06-03
AU2017201724B2 (en) 2019-01-17
WO2014036345A3 (en) 2014-06-26
EP2890393A2 (en) 2015-07-08
CA2883296A1 (en) 2014-03-06
MD20150031A2 (ro) 2015-10-31
US20140065187A1 (en) 2014-03-06
EA031988B1 (ru) 2019-03-29
US9315553B2 (en) 2016-04-19
NZ715459A (en) 2017-05-26
US10364274B2 (en) 2019-07-30
PH12015500700B1 (en) 2018-11-28
WO2014036345A2 (en) 2014-03-06
EP2890392B1 (en) 2019-04-17
BR112015004463B8 (pt) 2022-06-28
AU2013308627A1 (en) 2015-04-09
BR112015004463B1 (pt) 2021-08-24
HK1211874A1 (zh) 2016-06-03
EP2890392A1 (en) 2015-07-08
RU2647568C2 (ru) 2018-03-16
KR20150063403A (ko) 2015-06-09
RU2015111255A (ru) 2016-10-20
NZ705790A (en) 2016-06-24
CN108578679A (zh) 2018-09-28
AU2013308623A1 (en) 2015-04-02
US20140072594A1 (en) 2014-03-13
WO2014036349A1 (en) 2014-03-06
JP6405308B2 (ja) 2018-10-17
MX2021004478A (es) 2021-06-04
MX358782B (es) 2018-09-04
CN104717976A (zh) 2015-06-17
AP2015008331A0 (en) 2015-03-31
JP2015528466A (ja) 2015-09-28
JP2015529462A (ja) 2015-10-08
US9169302B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
AU2017201724B2 (en) Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing
Hajam et al. Bacterial ghosts as adjuvants: mechanisms and potential
CN101730541B (zh) 作为传染性病原体或毒素相关疾病的疫苗佐剂的细胞外基质材料
Datta et al. Vaccination with irradiated Listeria induces protective T cell immunity
US20110014184A1 (en) Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions
TR201815419T4 (tr) Ospa'nin mutant fragmanlari ve bunlarla i̇lgi̇li̇ yöntemler ve kullanimlar
EA036764B1 (ru) Ослабленный штамм streptococcus suis, индуцирующий иммунный ответ у свиней, и его применение
Azevedo et al. Human leptospirosis: In search for a better vaccine
US20220105178A1 (en) Li vaccine adjuvant
CN105682680A (zh) 增强对结核病的免疫
JP6456437B2 (ja) マイコプラズマ抗原を含む免疫原性組成物
JP4653934B2 (ja) バクテリオファージによって仲介される免疫化方法
US10080791B2 (en) Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
Li et al. A Bacterial mRNA‐Lysis‐Mediated Cargo Release Vaccine System for Regulated Cytosolic Surveillance and Optimized Antigen Delivery
GB2570806A (en) Immunogenic agent and associated compositions, uses and methods
Oledzka et al. Toxoplasma gondii: Immunological response of sheep to injections of recombinant SAG1, SAG2, GRA1 proteins coupled to the non-toxic microparticle muramyl dipeptide
CN102481358A (zh) 对抗蓝舌病毒的异源性引发-加强免疫疗法
Nagdive et al. Protective Efficiency of Pasteurella multocida A: 1 Bacteriophage lysate Vaccine against Homologous and Heterologous Challenge in Poultry
De Melo Barbosa Production Technologies, Regulatory Parameters, and Quality Control of Vaccine Vectors for Veterinary Use
Salvador-Mira et al. Erythrocyte-Targeted Recombinant Subunit Vaccine: A Novel Approach to Improve Viral Vaccines in Fish
RU2643335C1 (ru) Инактивированная бивалентная гидроокись алюминиевая вакцина против кампилобактериоза собак
Wellemans et al. Immunostimulatory properties of a novel adjuvant administered with inactivated influenza virus vaccine
Kemp et al. Mucosal immunization of mice with a recombinant Salmonella choleraesuis that expresses a multimeric gonadotropin releasing hormone fusion protein
DNA-Based Marked Enhancement of the
HK1146238A (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)